Eyam Health https://eyamhealth.com/ Eyam Health Wed, 08 Jan 2025 20:23:56 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.1 https://eyamhealth.com/wp-content/uploads/2023/10/cropped-eyamlogo-removebg-preview36-32x32.png Eyam Health https://eyamhealth.com/ 32 32 Veteran Leaders in Business and Pharma Join Eyam Health’s Board of Directors https://eyamhealth.com/veteran-leaders-in-business-and-pharma-join-eyam-healths-board-of-directors/?utm_source=rss&utm_medium=rss&utm_campaign=veteran-leaders-in-business-and-pharma-join-eyam-healths-board-of-directors https://eyamhealth.com/veteran-leaders-in-business-and-pharma-join-eyam-healths-board-of-directors/#respond Wed, 08 Jan 2025 18:30:45 +0000 https://eyamhealth.com/?p=3795 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Veteran Leaders in Business and Pharma Join Eyam Health’s Board of Directors appeared first on Eyam Health.

]]>

Veteran Leaders in Business and Pharma Join Eyam Health’s Board of Directors

VANCOUVER, BRITISH COLUMBIA, CANADA, January 8, 2025 /EINPresswire.com/ -- Eyam Health is proud to announce the appointments of Mary Filippelli and Lana Hoogenboom to its Board of Directors. The additions of Mary and Lana highlight Eyam’s ongoing commitment to strengthening its focus on business development and governance excellence.

Mary Filippelli: A Global Executive Driving Strategic Growth and Governance Excellence

Eyam is proud to welcome Mary Filippelli to its Board of Directors. With decades of experience as a senior executive and corporate director, Mary is a proven leader in driving organizational transformation, operational excellence, and governance across major global organizations.

Mary has held key executive positions, including Vice Chair and Managing Partner at Deloitte Canada, where she led the Deloitte’s customer experience strategy, implementing innovative solutions that delivered substantial revenue growth. Her prior executive global roles at Lloyds Banking Group and KPMG further demonstrate her ability to navigate complex global environments, accelerate market expansion and deliver impactful results. Mary’s board experience includes public, private and not-for profit boards, where she is considered a financial expert.

“Mary’s wealth of experience in governance and strategic transformation will be invaluable as Eyam continues to expand its global impact,” Eyam Chief Executive Officer, Ryan M. Thomas remarked. “Her proven leadership and deep expertise in driving organizational excellence make her a tremendous asset to our Board and to our mission of revolutionizing healthcare through cutting-edge innovation.”

Responding to her appointment, Mary commented, “I am honored to join Eyam’s Board of Directors at such an exciting time for the company. Eyam’s commitment to addressing global health challenges with transformative technologies aligns perfectly with my passion for driving meaningful change and fostering sustainable growth. I look forward to contributing to Eyam’s ambitious vision.”

Lana Hoogenboom: A Leader Driving Pharma Revenue Growth and Market Expansion

Eyam is delighted to announce Lana Hoogenboom to the Board. Lana brings a wealth of experience in sales strategy, business development, and global market expansion. Throughout her career, she has consistently demonstrated her ability to drive revenue growth and scale operations in competitive industries. Lana has held pivotal roles at pharmaceutical companies including GlaxoSmithKline, Janssen and Otsuka Canada Pharmaceutical where she leveraged her deep understanding of the market to develop innovative sales processes and increase market share. During her career, she identified new business opportunities, implemented customer-centric strategies, and drove product adoption in competitive therapeutic areas. During her tenure, Lana focused on collaborating with cross-functional teams to successfully launch new products and establish long-term customer relationships.

Regarding Lana’s appointment, Thomas noted, “Lana’s exceptional track record in sales strategy and market expansion will be instrumental as we work to bring Eyam’s innovations to the patients and markets that need them most. Her insights and expertise will help us scale our impact and realize the full potential of our advanced platforms.”

Regarding her appointment to the Eyam Board, Lana remarked, “I’m excited to join Eyam’s Board of Directors and to contribute to the commercialization of its groundbreaking technologies. Eyam’s focus on innovation and accessibility presents a unique opportunity to make a significant difference in healthcare worldwide, and I’m eager to support that journey.”

These new appointments come on the heels of Eyam’s recent announcement of its name change to Eyam Health, signaling an inflection point in Eyam’s growth and maturity of its mission and vision.

About Eyam:

Eyam Health is a leader in the development and commercialization of advanced vaccine and therapeutic enabling technologies. With a focus on four critical areas—infectious disease, oncology, chronic disease, and animal health—Eyam seeks to revolutionize health solutions across the globe. Founded in 2020, Eyam’s innovative platforms, including the Gemini and Jennerator technologies, continue to shape the future of medicine. The company is committed to carrying forward the legacy of Eyam’s historic namesake by developing transformative solutions that address the world’s most pressing health challenges.

Contact Information:

Samad Raza
Eyam Health
+1 604-767-4890

Veteran Leaders in Business and Pharma Join Eyam Health’s Board of Directors

VANCOUVER, BRITISH COLUMBIA, CANADA, January 8, 2025 /EINPresswire.com/ -- Eyam Health is proud to announce the appointments of Mary Filippelli and Lana Hoogenboom to its Board of Directors. The additions of Mary and Lana highlight Eyam’s ongoing commitment to strengthening its focus on business development and governance excellence.

Mary Filippelli: A Global Executive Driving Strategic Growth and Governance Excellence

Eyam is proud to welcome Mary Filippelli to its Board of Directors. With decades of experience as a senior executive and corporate director, Mary is a proven leader in driving organizational transformation, operational excellence, and governance across major global organizations.

Mary has held key executive positions, including Vice Chair and Managing Partner at Deloitte Canada, where she led the Deloitte’s customer experience strategy, implementing innovative solutions that delivered substantial revenue growth. Her prior executive global roles at Lloyds Banking Group and KPMG further demonstrate her ability to navigate complex global environments, accelerate market expansion and deliver impactful results. Mary’s board experience includes public, private and not-for profit boards, where she is considered a financial expert.

“Mary’s wealth of experience in governance and strategic transformation will be invaluable as Eyam continues to expand its global impact,” Eyam Chief Executive Officer, Ryan M. Thomas remarked. “Her proven leadership and deep expertise in driving organizational excellence make her a tremendous asset to our Board and to our mission of revolutionizing healthcare through cutting-edge innovation.”

Responding to her appointment, Mary commented, “I am honored to join Eyam’s Board of Directors at such an exciting time for the company. Eyam’s commitment to addressing global health challenges with transformative technologies aligns perfectly with my passion for driving meaningful change and fostering sustainable growth. I look forward to contributing to Eyam’s ambitious vision.”

Lana Hoogenboom: A Leader Driving Pharma Revenue Growth and Market Expansion

Eyam is delighted to announce Lana Hoogenboom to the Board. Lana brings a wealth of experience in sales strategy, business development, and global market expansion. Throughout her career, she has consistently demonstrated her ability to drive revenue growth and scale operations in competitive industries. Lana has held pivotal roles at pharmaceutical companies including GlaxoSmithKline, Janssen and Otsuka Canada Pharmaceutical where she leveraged her deep understanding of the market to develop innovative sales processes and increase market share. During her career, she identified new business opportunities, implemented customer-centric strategies, and drove product adoption in competitive therapeutic areas. During her tenure, Lana focused on collaborating with cross-functional teams to successfully launch new products and establish long-term customer relationships.

Regarding Lana’s appointment, Thomas noted, “Lana’s exceptional track record in sales strategy and market expansion will be instrumental as we work to bring Eyam’s innovations to the patients and markets that need them most. Her insights and expertise will help us scale our impact and realize the full potential of our advanced platforms.”

Regarding her appointment to the Eyam Board, Lana remarked, “I’m excited to join Eyam’s Board of Directors and to contribute to the commercialization of its groundbreaking technologies. Eyam’s focus on innovation and accessibility presents a unique opportunity to make a significant difference in healthcare worldwide, and I’m eager to support that journey.”

These new appointments come on the heels of Eyam’s recent announcement of its name change to Eyam Health, signaling an inflection point in Eyam’s growth and maturity of its mission and vision.

About Eyam:

Eyam Health is a leader in the development and commercialization of advanced vaccine and therapeutic enabling technologies. With a focus on four critical areas—infectious disease, oncology, chronic disease, and animal health—Eyam seeks to revolutionize health solutions across the globe. Founded in 2020, Eyam’s innovative platforms, including the Gemini and Jennerator technologies, continue to shape the future of medicine. The company is committed to carrying forward the legacy of Eyam’s historic namesake by developing transformative solutions that address the world’s most pressing health challenges.

Contact Information:

Samad Raza
Eyam Health
+1 604-767-4890

Share this post

The Latest

The post Veteran Leaders in Business and Pharma Join Eyam Health’s Board of Directors appeared first on Eyam Health.

]]> https://eyamhealth.com/veteran-leaders-in-business-and-pharma-join-eyam-healths-board-of-directors/feed/ 0 Eyam Health Announces Corporate Name Change to Reflect Expanded Mission and Technological Advancements https://eyamhealth.com/eyam-health-announces-corporate-name-change-to-reflect-expanded-mission-and-technological-advancements/?utm_source=rss&utm_medium=rss&utm_campaign=eyam-health-announces-corporate-name-change-to-reflect-expanded-mission-and-technological-advancements https://eyamhealth.com/eyam-health-announces-corporate-name-change-to-reflect-expanded-mission-and-technological-advancements/#respond Mon, 06 Jan 2025 19:12:41 +0000 https://eyamhealth.com/?p=3789 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Eyam Health Announces Corporate Name Change to Reflect Expanded Mission and Technological Advancements appeared first on Eyam Health.

]]>

Eyam Health Announces Corporate Name Change to Reflect Expanded Mission and Technological Advancements

VANCOUVER, BRITISH COLUMBIA, CANADA, January 6, 2025 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is rebranding to Eyam Health, effective January 2025. This change underscores the company’s broader mission to address global health challenges through innovative solutions and advanced technologies.

Founded in 2020, Eyam has developed groundbreaking technologies, including its Gemini and Jennerator platforms, which enable precise delivery of vaccines and therapeutics. These platforms have set new benchmarks in treating infectious diseases, chronic illnesses, cancer, and veterinary health. Eyam’s advancements are helping shape the future of healthcare, with innovative solutions for both human and animal health.

“We are now at a pivotal moment in Eyam’s journey,” stated Ryan M. Thomas, CEO of Eyam Health. “With expanded partnerships and significant progress in our internal programs, we are better positioned than ever to deliver transformative health solutions. . This rebrand reflects our dedication to solving global health challenges and revolutionizing the healthcare landscape.”

Technological Advancements with Global Reach

Eyam’s Gemini Platform along with its AI-powered Jennerator platform, are key drivers of the company’s success. These platforms accelerate the design and delivery of vaccines and therapeutics while addressing critical health challenges. Notably, Eyam’s innovative cold-storage free delivery system ensures accessibility and cost-effectiveness, paving the way for global deployment of life-saving treatments.

Eyam is also deepening its commitment to animal health through strategic partnerships and promising ongoing studies that showcase the versatility of its platforms.

A Name that Honors a Legacy of Resilience

The new name, Eyam Health, pays tribute to the historic village of Eyam in Derbyshire, England.
During the plague outbreak of 1665, the villagers’ courageous decision to self-quarantine prevented the disease from spreading further. Their heroism symbolizes the resilience and commitment to the greater good that inspires Eyam Health’s mission today.

“Much like the brave villagers of Eyam, we are motivated to develop solutions that prevent the spread of disease and make a lasting impact on global health,” added Thomas.

About Eyam Health

Eyam Health is at the forefront of developing and commercializing advanced vaccine and therapeutic enabling technologies. With a focus on four critical areas—infectious disease, oncology, chronic disease, and animal health—Eyam seeks to revolutionize health solutions across the globe. Founded in 2020, Eyam’s innovative platforms, including the Gemini and Jennerator technologies, continue to shape the future of medicine. The company is committed to carrying forward the legacy of Eyam’s historic namesake by developing transformative solutions that address the world’s most pressing health challenges.

For media inquiries, please contact:

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 778-381-1075
email us here

Eyam Health Announces Corporate Name Change to Reflect Expanded Mission and Technological Advancements

VANCOUVER, BRITISH COLUMBIA, CANADA, January 6, 2025 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is rebranding to Eyam Health, effective January 2025. This change underscores the company’s broader mission to address global health challenges through innovative solutions and advanced technologies.

Founded in 2020, Eyam has developed groundbreaking technologies, including its Gemini and Jennerator platforms, which enable precise delivery of vaccines and therapeutics. These platforms have set new benchmarks in treating infectious diseases, chronic illnesses, cancer, and veterinary health. Eyam’s advancements are helping shape the future of healthcare, with innovative solutions for both human and animal health.

“We are now at a pivotal moment in Eyam’s journey,” stated Ryan M. Thomas, CEO of Eyam Health. “With expanded partnerships and significant progress in our internal programs, we are better positioned than ever to deliver transformative health solutions. . This rebrand reflects our dedication to solving global health challenges and revolutionizing the healthcare landscape.”

Technological Advancements with Global Reach

Eyam’s Gemini Platform along with its AI-powered Jennerator platform, are key drivers of the company’s success. These platforms accelerate the design and delivery of vaccines and therapeutics while addressing critical health challenges. Notably, Eyam’s innovative cold-storage free delivery system ensures accessibility and cost-effectiveness, paving the way for global deployment of life-saving treatments.

Eyam is also deepening its commitment to animal health through strategic partnerships and promising ongoing studies that showcase the versatility of its platforms.

A Name that Honors a Legacy of Resilience

The new name, Eyam Health, pays tribute to the historic village of Eyam in Derbyshire, England.
During the plague outbreak of 1665, the villagers’ courageous decision to self-quarantine prevented the disease from spreading further. Their heroism symbolizes the resilience and commitment to the greater good that inspires Eyam Health’s mission today.

“Much like the brave villagers of Eyam, we are motivated to develop solutions that prevent the spread of disease and make a lasting impact on global health,” added Thomas.

About Eyam Health

Eyam Health is at the forefront of developing and commercializing advanced vaccine and therapeutic enabling technologies. With a focus on four critical areas—infectious disease, oncology, chronic disease, and animal health—Eyam seeks to revolutionize health solutions across the globe. Founded in 2020, Eyam’s innovative platforms, including the Gemini and Jennerator technologies, continue to shape the future of medicine. The company is committed to carrying forward the legacy of Eyam’s historic namesake by developing transformative solutions that address the world’s most pressing health challenges.

For media inquiries, please contact:

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 778-381-1075
email us here

Share this post

The Latest

The post Eyam Health Announces Corporate Name Change to Reflect Expanded Mission and Technological Advancements appeared first on Eyam Health.

]]> https://eyamhealth.com/eyam-health-announces-corporate-name-change-to-reflect-expanded-mission-and-technological-advancements/feed/ 0 Eyam Announces Professor Janet Hemingway’s Appointment to Board of Advisors https://eyamhealth.com/eyam-announces-professor-janet-hemingways-appointment-to-board-of-advisors/?utm_source=rss&utm_medium=rss&utm_campaign=eyam-announces-professor-janet-hemingways-appointment-to-board-of-advisors Wed, 13 Nov 2024 07:00:34 +0000 https://eyamhealth.com/?p=3784 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Eyam Announces Professor Janet Hemingway’s Appointment to Board of Advisors appeared first on Eyam Health.

]]>

Eyam Announces Professor Janet Hemingway’s Appointment to Board of Advisors

VANCOUVER, CANADA, November 13, 2024 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is proud to announce the appointment of Professor Janet Hemingway to its Board of Advisors. A world-renowned expert in tropical medicine and vector-borne diseases, Professor Hemingway brings over four decades of groundbreaking research, leadership, and strategic vision in global public health to Eyam.

Professor Hemingway has held pivotal roles at leading health organizations, including her transformative leadership at the Liverpool School of Tropical Medicine (LSTM), where she served as Director from 2001 to 2019. During this time, she was awarded the Commander of the British Empire (CBE) for services to the Control of Tropical Disease Vectors 2012. Under her guidance, LSTM evolved into a global powerhouse in tropical disease research and capacity-building, particularly focusing on vector-borne illnesses. In 2020 Janet set up and became the Founding Director for the Infection Innovation Consortium (iiCON). In just 4 years iiCON has achieved a portfolio value of £222.3 million, connected 1009 organizations Worldwide, and created 770 jobs.

“With her deep expertise in translating cutting-edge research into impactful public health interventions, Professor Hemingway has significantly advanced global health outcomes. She has been instrumental in developing novel approaches for controlling vectors of infectious diseases, driving collaboration between public, private, and academic sectors,” Eyam CEO, Ryan M. Thomas said about the appointment.

Thomas continued by saying, “We are happy to welcome Professor Hemingway to our Board of Advisors. Her extensive experience in translating scientific research into real-world health solutions aligns with Eyam’s mission to address critical global health challenges. Her leadership in combating vector-borne diseases, along with her strategic insights, will be invaluable as we expand our platform to tackle infectious diseases, chronic conditions, and beyond.”

Professor Hemingway also shared her enthusiasm for joining Eyam: “I am honored to join Eyam’s Board of Advisors at such an exciting time in the company’s growth. Eyam’s innovative approaches to vaccine and therapeutic development, particularly in infectious diseases, represent the next frontier in global health interventions. I look forward to contributing to Eyam’s efforts to deliver impactful solutions that will address some of the most pressing health challenges worldwide.”

Professor Hemingway’s appointment represents a pivotal step in Eyam’s continued strategic development. Her addition to the Board underscores Eyam’s commitment to enhancing research collaborations, accelerating innovations in biotechnology, and delivering next-generation health solutions across infectious diseases, oncology, and chronic conditions.

This appointment further positions Eyam to expand its global footprint and strengthen partnerships with leading institutions, all while driving its mission to revolutionize healthcare.

About Eyam:
Eyam is at the forefront of developing and commercializing advanced vaccine and therapeutic platforms. The company is focused on four critical areas: infectious disease, oncology, chronic disease, and animal health. Eyam is named in honor of the historic plague village in Derbyshire, England, where residents made the heroic choice to quarantine themselves to prevent the spread of plague in 1665. Today, Eyam seeks to honor that legacy by advancing next-generation technologies aimed at preventing and treating diseases worldwide.

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 604-767-4890

email us here
Visit us on social media:
LinkedIn

Eyam Announces Professor Janet Hemingway’s Appointment to Board of Advisors

VANCOUVER, CANADA, November 13, 2024 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is proud to announce the appointment of Professor Janet Hemingway to its Board of Advisors. A world-renowned expert in tropical medicine and vector-borne diseases, Professor Hemingway brings over four decades of groundbreaking research, leadership, and strategic vision in global public health to Eyam.

Professor Hemingway has held pivotal roles at leading health organizations, including her transformative leadership at the Liverpool School of Tropical Medicine (LSTM), where she served as Director from 2001 to 2019. During this time, she was awarded the Commander of the British Empire (CBE) for services to the Control of Tropical Disease Vectors 2012. Under her guidance, LSTM evolved into a global powerhouse in tropical disease research and capacity-building, particularly focusing on vector-borne illnesses. In 2020 Janet set up and became the Founding Director for the Infection Innovation Consortium (iiCON). In just 4 years iiCON has achieved a portfolio value of £222.3 million, connected 1009 organizations Worldwide, and created 770 jobs.

“With her deep expertise in translating cutting-edge research into impactful public health interventions, Professor Hemingway has significantly advanced global health outcomes. She has been instrumental in developing novel approaches for controlling vectors of infectious diseases, driving collaboration between public, private, and academic sectors,” Eyam CEO, Ryan M. Thomas said about the appointment.

Thomas continued by saying, “We are happy to welcome Professor Hemingway to our Board of Advisors. Her extensive experience in translating scientific research into real-world health solutions aligns with Eyam’s mission to address critical global health challenges. Her leadership in combating vector-borne diseases, along with her strategic insights, will be invaluable as we expand our platform to tackle infectious diseases, chronic conditions, and beyond.”

Professor Hemingway also shared her enthusiasm for joining Eyam: “I am honored to join Eyam’s Board of Advisors at such an exciting time in the company’s growth. Eyam’s innovative approaches to vaccine and therapeutic development, particularly in infectious diseases, represent the next frontier in global health interventions. I look forward to contributing to Eyam’s efforts to deliver impactful solutions that will address some of the most pressing health challenges worldwide.”

Professor Hemingway’s appointment represents a pivotal step in Eyam’s continued strategic development. Her addition to the Board underscores Eyam’s commitment to enhancing research collaborations, accelerating innovations in biotechnology, and delivering next-generation health solutions across infectious diseases, oncology, and chronic conditions.

This appointment further positions Eyam to expand its global footprint and strengthen partnerships with leading institutions, all while driving its mission to revolutionize healthcare.

About Eyam:
Eyam is at the forefront of developing and commercializing advanced vaccine and therapeutic platforms. The company is focused on four critical areas: infectious disease, oncology, chronic disease, and animal health. Eyam is named in honor of the historic plague village in Derbyshire, England, where residents made the heroic choice to quarantine themselves to prevent the spread of plague in 1665. Today, Eyam seeks to honor that legacy by advancing next-generation technologies aimed at preventing and treating diseases worldwide.

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 604-767-4890

email us here
Visit us on social media:
LinkedIn

Share this post

The Latest

The post Eyam Announces Professor Janet Hemingway’s Appointment to Board of Advisors appeared first on Eyam Health.

]]> Eyam Expands Strategic Partnerships in Animal Health Driving Commercial Growth https://eyamhealth.com/eyam-expands-strategic-partnerships-in-animal-health-driving-commercial-growth/?utm_source=rss&utm_medium=rss&utm_campaign=eyam-expands-strategic-partnerships-in-animal-health-driving-commercial-growth Thu, 31 Oct 2024 17:27:53 +0000 https://eyamhealth.com/?p=3780 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Eyam Expands Strategic Partnerships in Animal Health Driving Commercial Growth appeared first on Eyam Health.

]]>

Eyam Expands Strategic Partnerships in Animal Health Driving Commercial Growth

VANCOUVER, CANADA, October 31, 2024 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is excited to announce a new partnership with a global leader in animal health. This new agreement is the second partnership for Eyam within the animal health industry and reinforces its role as an emerging innovator in this rapidly growing market.

The partnership focuses on advancing solutions for disease prevention and treatment in the animal health sector, which is experiencing strong global growth, expecting to generate more than $75 billion in revenue in 2025 and to grow at over 9% per year. This collaboration will leverage Eyam’s Gemini expression system to enhance the delivery, effectiveness and duration of an antibody therapeutic and highlights Eyam’s ability to apply its expertise in new areas while also opening new revenue opportunities in a booming sector.

“Our expanding partnerships reflect the increasing demand for advanced therapeutic solutions across various sectors,” said Ryan M. Thomas, CEO of Eyam. “This collaboration demonstrates the industry's growing trust in our capacity to deliver impactful solutions. By joining forces with global leaders in both human and animal health, Eyam is well-positioned to seize new commercial opportunities and accelerate our growth.”

This agreement is the latest in a series of strategic collaborations, underscoring Eyam’s commitment to scaling its presence in high-demand markets. Results from recent projects are expected later this year, signaling the strong commercial potential of Eyam’s technologies within the animal health sector.

With a growing number of partnerships across diverse industries, Eyam is poised to scale its operations and drive commercial success. By addressing unmet needs in animal health, while also tackling broader global health challenges, the company is ensuring sustained leadership and growth in the dynamic biotech and health markets.

About Eyam Vaccines and Immunotherapeutics:

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, visit www.eyamhealth.com or contact:

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 604-767-4890
email us here
Visit us on social media:
LinkedIn

Eyam Expands Strategic Partnerships in Animal Health Driving Commercial Growth

VANCOUVER, CANADA, October 31, 2024 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is excited to announce a new partnership with a global leader in animal health. This new agreement is the second partnership for Eyam within the animal health industry and reinforces its role as an emerging innovator in this rapidly growing market.

The partnership focuses on advancing solutions for disease prevention and treatment in the animal health sector, which is experiencing strong global growth, expecting to generate more than $75 billion in revenue in 2025 and to grow at over 9% per year. This collaboration will leverage Eyam’s Gemini expression system to enhance the delivery, effectiveness and duration of an antibody therapeutic and highlights Eyam’s ability to apply its expertise in new areas while also opening new revenue opportunities in a booming sector.

“Our expanding partnerships reflect the increasing demand for advanced therapeutic solutions across various sectors,” said Ryan M. Thomas, CEO of Eyam. “This collaboration demonstrates the industry's growing trust in our capacity to deliver impactful solutions. By joining forces with global leaders in both human and animal health, Eyam is well-positioned to seize new commercial opportunities and accelerate our growth.”

This agreement is the latest in a series of strategic collaborations, underscoring Eyam’s commitment to scaling its presence in high-demand markets. Results from recent projects are expected later this year, signaling the strong commercial potential of Eyam’s technologies within the animal health sector.

With a growing number of partnerships across diverse industries, Eyam is poised to scale its operations and drive commercial success. By addressing unmet needs in animal health, while also tackling broader global health challenges, the company is ensuring sustained leadership and growth in the dynamic biotech and health markets.

About Eyam Vaccines and Immunotherapeutics:

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, visit www.eyamhealth.com or contact:

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 604-767-4890
email us here
Visit us on social media:
LinkedIn

Share this post

The Latest

The post Eyam Expands Strategic Partnerships in Animal Health Driving Commercial Growth appeared first on Eyam Health.

]]> Eyam Partners with Global Animal Health Leader to Expand Commercial Opportunities in Therapeutics https://eyamhealth.com/eyam-partners-with-global-animal-health-leader-to-expand-commercial-opportunities-in-therapeutics/?utm_source=rss&utm_medium=rss&utm_campaign=eyam-partners-with-global-animal-health-leader-to-expand-commercial-opportunities-in-therapeutics Tue, 29 Oct 2024 19:15:51 +0000 https://eyamhealth.com/?p=3778 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Eyam Partners with Global Animal Health Leader to Expand Commercial Opportunities in Therapeutics appeared first on Eyam Health.

]]>

Eyam Partners with Global Animal Health Leader to Expand Commercial Opportunities in Therapeutics

VANCOUVER, CANADA, October 29, 2024 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is proud to announce a strategic partnership with a global leader in animal health, marking a pivotal moment in the company’s commercial expansion. This collaboration harnesses Eyam’s cutting-edge biotechnology, opening doors to new markets within the rapidly growing animal health sector.

The partnership will focus on developing innovative solutions for disease prevention and treatment, utilizing Eyam’s proprietary platform to create advanced therapeutics designed to address unmet needs in animal care. With the global animal health market projected to be $75 billion in 2025, this collaboration represents a significant growth opportunity for Eyam, broadening the company’s impact beyond human health.

“This partnership is a testament to Eyam’s commitment to scaling our groundbreaking technologies into new, high-demand areas like animal health,” said Ryan M. Thomas, CEO of Eyam. “By collaborating with a leader in this space, we’re positioned to unlock substantial commercial potential and diversify our presence across industries.”

As Eyam continues to forge strategic alliances, the company remains dedicated to delivering innovative solutions that address global health challenges. This collaboration underscores Eyam’s leadership in the biotech space and sets the stage for continued growth and market expansion.

About Eyam Vaccines and Immunotherapeutics:

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, visit www.eyamhealth.com or contact:

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 778-381-1075
Visit us on social media:
LinkedIn

Eyam Partners with Global Animal Health Leader to Expand Commercial Opportunities in Therapeutics

VANCOUVER, CANADA, October 29, 2024 /EINPresswire.com/ -- Eyam Vaccines and Immunotherapeutics is proud to announce a strategic partnership with a global leader in animal health, marking a pivotal moment in the company’s commercial expansion. This collaboration harnesses Eyam’s cutting-edge biotechnology, opening doors to new markets within the rapidly growing animal health sector.

The partnership will focus on developing innovative solutions for disease prevention and treatment, utilizing Eyam’s proprietary platform to create advanced therapeutics designed to address unmet needs in animal care. With the global animal health market projected to be $75 billion in 2025, this collaboration represents a significant growth opportunity for Eyam, broadening the company’s impact beyond human health.

“This partnership is a testament to Eyam’s commitment to scaling our groundbreaking technologies into new, high-demand areas like animal health,” said Ryan M. Thomas, CEO of Eyam. “By collaborating with a leader in this space, we’re positioned to unlock substantial commercial potential and diversify our presence across industries.”

As Eyam continues to forge strategic alliances, the company remains dedicated to delivering innovative solutions that address global health challenges. This collaboration underscores Eyam’s leadership in the biotech space and sets the stage for continued growth and market expansion.

About Eyam Vaccines and Immunotherapeutics:

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, visit www.eyamhealth.com or contact:

Samad Raza
Eyam Vaccines and Immunotherapeutics
+1 778-381-1075
Visit us on social media:
LinkedIn

Share this post

The Latest

The post Eyam Partners with Global Animal Health Leader to Expand Commercial Opportunities in Therapeutics appeared first on Eyam Health.

]]> Innovating Animal Health with Eyam’s Cost-Effective, Long-Lasting Vaccines https://eyamhealth.com/innovating-animal-health-with-eyams-cost-effective-long-lasting-vaccines/?utm_source=rss&utm_medium=rss&utm_campaign=innovating-animal-health-with-eyams-cost-effective-long-lasting-vaccines Tue, 08 Oct 2024 22:06:03 +0000 https://eyamhealth.com/?p=3738 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Innovating Animal Health with Eyam’s Cost-Effective, Long-Lasting Vaccines appeared first on Eyam Health.

]]>

Innovating Animal Health with Eyam’s Cost-Effective, Long-Lasting Vaccines

October 08, 2024

By Ryan M. Thomas
As Eyam continues its mission to drive innovation in the biotech space, this month, we are spotlighting a critical and often under-discussed sector: the Animal Health Industry. 

Why are we highlighting the Animal Health Industry this month? 

  1. Food Security: The health of livestock and other animals is directly linked to global food security. Healthy animals contribute to the stability of food systems by ensuring a steady supply of meat, dairy, and other animal products. By focusing on innovations in animal health, Eyam can help prevent diseases that could disrupt food production, ensuring a more resilient global food chain.
  2. Zoonotic Diseases: Many diseases that affect humans originate from animals (zoonotic diseases), including viruses like SARS, MERS, and COVID-19. Developing vaccines and therapies to protect animals from these diseases reduces the risk of transmission to humans, supporting global public health efforts.
  3. Business Opportunities: The animal health sector is a rapidly growing market with significant commercial potential. Innovations in vaccines and treatments for animals present new business avenues, not only for combating diseases but also for enhancing the overall well-being of pets and livestock, opening up opportunities for partnerships and expansion in this sector.

This month, Eyam is poised to begin 2 new partnership studies with large animal health pharmaceuticals. The details are still confidential, but there are several reasons why animal health pharmaceuticals are excited about Eyam’s technologies:

  1. Cost of Goods: One of the most compelling advantages of Eyam’s DNA vaccine technology is its exceptionally low cost of production. Manufacturing these vaccines is highly scalable, and for Eyam’s product, the cost per dose may be as low as pennies on the dollar. This cost-efficiency is a major benefit in the animal health sector, where large-scale vaccinations are often necessary, making Eyam’s technology a game-changer for widespread disease prevention at an affordable price.
  2. Stability: Eyam’s DNA plasmid technology offers unparalleled stability, even under challenging conditions. The plasmids can be frozen and thawed multiple times without losing efficacy, maintaining their structural integrity. Moreover, they remain stable for longer periods and at higher temperatures compared to traditional vaccines. This makes distribution and storage more flexible, especially in regions with limited refrigeration capabilities, reducing logistical barriers in animal health applications.
  3. Durability: Eyam’s self-amplifying technologies offer a significant advantage in terms of prolonged expression power. This means that the vaccines can induce a stronger and longer-lasting immune response in animals, offering extended protection compared to conventional products. For animal health pharmaceuticals, this extended protection reduces the frequency of vaccinations or therapeutics, enhancing convenience for veterinarians and farmers while improving animal welfare.

These factors make Eyam’s platform highly attractive for the animal health industry, poised to revolutionize how vaccines are produced, stored, and administered. 

As an Eyam shareholder, why should you be excited about our penetration into this market?

  • Market Accessibility & Cost Efficiency

Global Reach: The extremely low cost of goods, with production potentially as low as pennies per dose, allows Eyam’s vaccines to be deployed at scale, particularly in regions with limited financial resources. In markets like livestock farming, where mass vaccination is often needed, this affordability becomes a key differentiator. For developing nations or large-scale agricultural sectors, this cost efficiency opens up opportunities to ensure widespread immunization without the financial strain typically associated with high-tech vaccines.

Potential for Public-Private Partnerships: Given the cost benefits, Eyam is working to collaborate with governmental and non-governmental organizations focused on global health, food security, and animal welfare. These partnerships can help expand Eyam’s reach, particularly in markets where animal diseases threaten food supply chains.

  • Extended Market Penetration with Durability

Fewer Interventions, Better Coverage: With Eyam’s self-amplifying technologies offering long-lasting immune protection, farmers and veterinarians need to vaccinate animals less frequently. This reduces labor and operational costs, particularly in industries such as poultry, cattle, and aquaculture, where large numbers of animals need regular care. Longer-lasting vaccines also ensure better compliance and greater overall coverage in the animal population, reducing the chances of disease outbreaks.

Niche Markets for High-Value Livestock: For high-value livestock (such as dairy cows, thoroughbred horses, or race animals), the durability and reliability of Eyam’s vaccines provide an attractive proposition. These animals require maximum health protection to maintain productivity, and longer-lasting vaccines help ensure minimal disruptions due to illness.

  • Strategic Partnerships in Established Markets

Collaborations with Major Animal Health Players: The global animal health market is dominated by a few large players. Eyam’s advanced vaccine platforms make it a valuable partner for these industry leaders, offering cutting-edge solutions that address some of the fundamental challenges in animal health, such as vaccine durability, efficacy, and production costs.

Licensing Opportunities: With strong intellectual property around these platforms, Eyam has the potential to license its technologies for specific applications across various species and diseases. Licensing to larger pharmaceutical firms with established global networks could fast-track Eyam’s technologies into the mainstream market while generating significant revenue streams.

  • Meeting the Needs of Emerging Health Threats

Zoonotic Disease Prevention: As many animal diseases also pose risks to human health, Eyam’s platform could play a crucial role in preventing zoonotic diseases. Vaccines developed using Eyam’s technologies could be instrumental in managing diseases that have the potential to jump from animals to humans, offering long-term protection against emerging threats like avian influenza, swine flu, or even future coronaviruses.

Responding to Climate Impacts: As the changing climate drives the spread of diseases across different regions, the flexibility and durability of Eyam’s vaccines make them well-suited to rapidly evolving disease landscapes. This positions Eyam as a key player in adapting to new health challenges driven by global environmental changes.

  • Sustainability and Ethical Standards

Reducing Antibiotic Use: Long-lasting vaccines contribute to reducing the need for antibiotics in animal health, aligning with global initiatives to combat antimicrobial resistance (AMR). Eyam’s technology can provide alternative solutions to antibiotics, positioning the company as a leader in sustainable animal health practices.

Animal Welfare: With fewer vaccinations required and longer protection provided, Eyam’s products aim to reduce the stress on animals from repeated handling and interventions. This not only improves animal welfare but also could enhance the overall productivity of farms and animal health operations.

The Animal Health  industry safeguards the health of livestock and companion animals, ensuring food security, mitigating zoonotic diseases, and supporting the broader global economy. Now, with Eyam’s novel nucleic acid platforms, we are poised to make a transformative impact. Our cutting-edge, low-cost, and long-lasting solutions promise to reshape how the industry approaches animal health, offering a future where prevention, accessibility, and efficacy go hand in hand.

The Animal Health Industry: An Overview

The global animal health market is a thriving, rapidly expanding sector, valued at over $50 billion in 2023, and showing no signs of slowing down. This industry spans a wide range of products, from vaccines and therapeutics to diagnostics and feed additives. Traditionally, the focus has been on managing diseases that threaten animal productivity, particularly in livestock, which directly impacts human food supply.

However, the landscape is evolving. In recent years, there has been a shift toward more innovative, sustainable, and humane disease control methods. Vaccines and biologics are rising to the forefront, fueled by increasing awareness of zoonotic diseases (those that can jump from animals to humans), regulatory pressures to reduce antibiotic use, and growing demand for higher standards of animal welfare. This is a sector ripe for disruption—and Eyam’s technology is poised to deliver exactly that.

The Economics Behind the Industry

What drives the animal health industry is the increasing global demand for protein. As populations grow, particularly in emerging markets, livestock production has surged, and with it, the need for comprehensive disease management strategies. The days of using antibiotics as a blanket preventative measure are fading; instead, vaccines and other biologics are becoming the new standard for ensuring healthy herds and flocks.

In 2023 alone, the global market for animal vaccines was valued at approximately $12 billion, with projections of a 6.5% annual growth rate over the next five years. This growth is fueled by the demand for safer, more effective, and environmentally sustainable disease prevention methods. Meanwhile, therapeutic products targeting chronic conditions in pets and livestock are also seeing increased demand, driven by consumer expectations for better care and long-term solutions.

This presents a unique opportunity for companies like Eyam, which are positioned to offer not only more effective treatments but also affordable and scalable solutions that can meet the rising global need.

The Importance of Preventive Medicine in Animal Health

Preventive medicine is rapidly becoming the cornerstone of the animal health industry. The old saying holds true: an ounce of prevention is worth a pound of cure. This shift toward prevention over treatment is not just a trend; it’s a necessity. For livestock producers, diseases like Bovine Respiratory Disease (BRD) or Foot-and-Mouth Disease (FMD) can devastate entire herds, leading to massive economic losses. Preventive vaccination programs are critical not only for reducing mortality but also for ensuring the sustainability of livestock operations worldwide.

In the companion animal sector, preventive care is just as important. Pet owners increasingly understand the value of routine vaccinations for diseases such as rabies and parvovirus. These vaccinations not only protect their pets but also serve a broader public health purpose by preventing zoonotic disease transmission. Recent studies show that every dollar invested in preventive care can save up to five dollars in future veterinary treatment costs.

Eyam’s self-amplifying DNA platform is uniquely suited to meet this growing demand. Our vaccines offer longer-lasting protection, requiring fewer doses and reducing overall costs for both producers and pet owners, all while maintaining exceptional efficacy.

The Search for Nucleic Acid Technologies

Nucleic acid technologies, like RNA and DNA-based vaccines, have gained widespread recognition in the human health sector, and they are now making their way into animal health. These technologies offer several key advantages: faster development, the ability to customize for specific pathogens, and more efficient manufacturing processes.

However, despite their promise, the adoption of nucleic acid vaccines in the animal health industry has been slow. The main barriers have been the high costs of production and the need for complex cold storage systems. This is where Eyam’s technology offers a game-changing solution.

Eyam’s Disruptive Approach: Low-Cost, Long-Lasting Self-Amplifying DNA Platforms

At Eyam, we have developed a disruptive platform that addresses the core limitations of traditional nucleic acid technologies. Our Gemini Self-Amplifying DNA platform offers the following advantages:

  1. Lower Cost of Production: Eyam’s self-amplifying DNA platform requires significantly smaller doses than traditional vaccines. This drastically reduces production costs, making it a more viable option for widespread use in livestock and companion animals, particularly in resource-constrained regions.
  2. No Cold Chain Required: Unlike most mRNA vaccines, our DNA-based vaccines are stable at ambient temperatures. This eliminates the need for expensive cold storage and transportation systems, which are significant barriers to vaccine distribution, especially in rural areas.
  3. Longer Duration of Efficacy: Our platform enables vaccines and therapeutics to have a much longer duration of action, which means fewer doses are needed. This not only reduces costs for producers but also increases the practicality of disease prevention on a large scale.
  4. Versatility Across Species and Pathogens: Our Gemini platform is adaptable to a wide range of pathogens and can be tailored to different animal species, making it a flexible tool for addressing multiple health challenges within the animal kingdom.

Eyam’s Role in the Future of Animal Health

The global animal health industry is growing, driven by economic pressures and the need for better disease control. Eyam is positioned at the forefront of this movement, offering transformative solutions that are not only cost-effective but also scalable and long-lasting. Our entrance into the animal health sector isn’t just a business opportunity—it’s a commitment to improving animal welfare, advancing global public health, and securing the future of our food systems.

Thank you for your continued trust and support as we forge new paths in innovation. Together, we are shaping the future of both human and animal health.

 

Innovating Animal Health with Eyam’s Cost-Effective, Long-Lasting Vaccines

October 08, 2024

By Ryan M. Thomas
As Eyam continues its mission to drive innovation in the biotech space, this month, we are spotlighting a critical and often under-discussed sector: the Animal Health Industry. 

Why are we highlighting the Animal Health Industry this month? 

  1. Food Security: The health of livestock and other animals is directly linked to global food security. Healthy animals contribute to the stability of food systems by ensuring a steady supply of meat, dairy, and other animal products. By focusing on innovations in animal health, Eyam can help prevent diseases that could disrupt food production, ensuring a more resilient global food chain.
  2. Zoonotic Diseases: Many diseases that affect humans originate from animals (zoonotic diseases), including viruses like SARS, MERS, and COVID-19. Developing vaccines and therapies to protect animals from these diseases reduces the risk of transmission to humans, supporting global public health efforts.
  3. Business Opportunities: The animal health sector is a rapidly growing market with significant commercial potential. Innovations in vaccines and treatments for animals present new business avenues, not only for combating diseases but also for enhancing the overall well-being of pets and livestock, opening up opportunities for partnerships and expansion in this sector.

This month, Eyam is poised to begin 2 new partnership studies with large animal health pharmaceuticals. The details are still confidential, but there are several reasons why animal health pharmaceuticals are excited about Eyam’s technologies:

  1. Cost of Goods: One of the most compelling advantages of Eyam’s DNA vaccine technology is its exceptionally low cost of production. Manufacturing these vaccines is highly scalable, and for Eyam’s product, the cost per dose may be as low as pennies on the dollar. This cost-efficiency is a major benefit in the animal health sector, where large-scale vaccinations are often necessary, making Eyam’s technology a game-changer for widespread disease prevention at an affordable price.
  2. Stability: Eyam’s DNA plasmid technology offers unparalleled stability, even under challenging conditions. The plasmids can be frozen and thawed multiple times without losing efficacy, maintaining their structural integrity. Moreover, they remain stable for longer periods and at higher temperatures compared to traditional vaccines. This makes distribution and storage more flexible, especially in regions with limited refrigeration capabilities, reducing logistical barriers in animal health applications.
  3. Durability: Eyam’s self-amplifying technologies offer a significant advantage in terms of prolonged expression power. This means that the vaccines can induce a stronger and longer-lasting immune response in animals, offering extended protection compared to conventional products. For animal health pharmaceuticals, this extended protection reduces the frequency of vaccinations or therapeutics, enhancing convenience for veterinarians and farmers while improving animal welfare.

These factors make Eyam’s platform highly attractive for the animal health industry, poised to revolutionize how vaccines are produced, stored, and administered. 

As an Eyam shareholder, why should you be excited about our penetration into this market?

  • Market Accessibility & Cost Efficiency

Global Reach: The extremely low cost of goods, with production potentially as low as pennies per dose, allows Eyam’s vaccines to be deployed at scale, particularly in regions with limited financial resources. In markets like livestock farming, where mass vaccination is often needed, this affordability becomes a key differentiator. For developing nations or large-scale agricultural sectors, this cost efficiency opens up opportunities to ensure widespread immunization without the financial strain typically associated with high-tech vaccines.

Potential for Public-Private Partnerships: Given the cost benefits, Eyam is working to collaborate with governmental and non-governmental organizations focused on global health, food security, and animal welfare. These partnerships can help expand Eyam’s reach, particularly in markets where animal diseases threaten food supply chains.

  • Extended Market Penetration with Durability

Fewer Interventions, Better Coverage: With Eyam’s self-amplifying technologies offering long-lasting immune protection, farmers and veterinarians need to vaccinate animals less frequently. This reduces labor and operational costs, particularly in industries such as poultry, cattle, and aquaculture, where large numbers of animals need regular care. Longer-lasting vaccines also ensure better compliance and greater overall coverage in the animal population, reducing the chances of disease outbreaks.

Niche Markets for High-Value Livestock: For high-value livestock (such as dairy cows, thoroughbred horses, or race animals), the durability and reliability of Eyam’s vaccines provide an attractive proposition. These animals require maximum health protection to maintain productivity, and longer-lasting vaccines help ensure minimal disruptions due to illness.

  • Strategic Partnerships in Established Markets

Collaborations with Major Animal Health Players: The global animal health market is dominated by a few large players. Eyam’s advanced vaccine platforms make it a valuable partner for these industry leaders, offering cutting-edge solutions that address some of the fundamental challenges in animal health, such as vaccine durability, efficacy, and production costs.

Licensing Opportunities: With strong intellectual property around these platforms, Eyam has the potential to license its technologies for specific applications across various species and diseases. Licensing to larger pharmaceutical firms with established global networks could fast-track Eyam’s technologies into the mainstream market while generating significant revenue streams.

  • Meeting the Needs of Emerging Health Threats

Zoonotic Disease Prevention: As many animal diseases also pose risks to human health, Eyam’s platform could play a crucial role in preventing zoonotic diseases. Vaccines developed using Eyam’s technologies could be instrumental in managing diseases that have the potential to jump from animals to humans, offering long-term protection against emerging threats like avian influenza, swine flu, or even future coronaviruses.

Responding to Climate Impacts: As the changing climate drives the spread of diseases across different regions, the flexibility and durability of Eyam’s vaccines make them well-suited to rapidly evolving disease landscapes. This positions Eyam as a key player in adapting to new health challenges driven by global environmental changes.

  • Sustainability and Ethical Standards

Reducing Antibiotic Use: Long-lasting vaccines contribute to reducing the need for antibiotics in animal health, aligning with global initiatives to combat antimicrobial resistance (AMR). Eyam’s technology can provide alternative solutions to antibiotics, positioning the company as a leader in sustainable animal health practices.

Animal Welfare: With fewer vaccinations required and longer protection provided, Eyam’s products aim to reduce the stress on animals from repeated handling and interventions. This not only improves animal welfare but also could enhance the overall productivity of farms and animal health operations.

The Animal Health  industry safeguards the health of livestock and companion animals, ensuring food security, mitigating zoonotic diseases, and supporting the broader global economy. Now, with Eyam’s novel nucleic acid platforms, we are poised to make a transformative impact. Our cutting-edge, low-cost, and long-lasting solutions promise to reshape how the industry approaches animal health, offering a future where prevention, accessibility, and efficacy go hand in hand.

The Animal Health Industry: An Overview

The global animal health market is a thriving, rapidly expanding sector, valued at over $50 billion in 2023, and showing no signs of slowing down. This industry spans a wide range of products, from vaccines and therapeutics to diagnostics and feed additives. Traditionally, the focus has been on managing diseases that threaten animal productivity, particularly in livestock, which directly impacts human food supply.

However, the landscape is evolving. In recent years, there has been a shift toward more innovative, sustainable, and humane disease control methods. Vaccines and biologics are rising to the forefront, fueled by increasing awareness of zoonotic diseases (those that can jump from animals to humans), regulatory pressures to reduce antibiotic use, and growing demand for higher standards of animal welfare. This is a sector ripe for disruption—and Eyam’s technology is poised to deliver exactly that.

The Economics Behind the Industry

What drives the animal health industry is the increasing global demand for protein. As populations grow, particularly in emerging markets, livestock production has surged, and with it, the need for comprehensive disease management strategies. The days of using antibiotics as a blanket preventative measure are fading; instead, vaccines and other biologics are becoming the new standard for ensuring healthy herds and flocks.

In 2023 alone, the global market for animal vaccines was valued at approximately $12 billion, with projections of a 6.5% annual growth rate over the next five years. This growth is fueled by the demand for safer, more effective, and environmentally sustainable disease prevention methods. Meanwhile, therapeutic products targeting chronic conditions in pets and livestock are also seeing increased demand, driven by consumer expectations for better care and long-term solutions.

This presents a unique opportunity for companies like Eyam, which are positioned to offer not only more effective treatments but also affordable and scalable solutions that can meet the rising global need.

The Importance of Preventive Medicine in Animal Health

Preventive medicine is rapidly becoming the cornerstone of the animal health industry. The old saying holds true: an ounce of prevention is worth a pound of cure. This shift toward prevention over treatment is not just a trend; it’s a necessity. For livestock producers, diseases like Bovine Respiratory Disease (BRD) or Foot-and-Mouth Disease (FMD) can devastate entire herds, leading to massive economic losses. Preventive vaccination programs are critical not only for reducing mortality but also for ensuring the sustainability of livestock operations worldwide.

In the companion animal sector, preventive care is just as important. Pet owners increasingly understand the value of routine vaccinations for diseases such as rabies and parvovirus. These vaccinations not only protect their pets but also serve a broader public health purpose by preventing zoonotic disease transmission. Recent studies show that every dollar invested in preventive care can save up to five dollars in future veterinary treatment costs.

Eyam’s self-amplifying DNA platform is uniquely suited to meet this growing demand. Our vaccines offer longer-lasting protection, requiring fewer doses and reducing overall costs for both producers and pet owners, all while maintaining exceptional efficacy.

The Search for Nucleic Acid Technologies

Nucleic acid technologies, like RNA and DNA-based vaccines, have gained widespread recognition in the human health sector, and they are now making their way into animal health. These technologies offer several key advantages: faster development, the ability to customize for specific pathogens, and more efficient manufacturing processes.

However, despite their promise, the adoption of nucleic acid vaccines in the animal health industry has been slow. The main barriers have been the high costs of production and the need for complex cold storage systems. This is where Eyam’s technology offers a game-changing solution.

Eyam’s Disruptive Approach: Low-Cost, Long-Lasting Self-Amplifying DNA Platforms

At Eyam, we have developed a disruptive platform that addresses the core limitations of traditional nucleic acid technologies. Our Gemini Self-Amplifying DNA platform offers the following advantages:

  1. Lower Cost of Production: Eyam’s self-amplifying DNA platform requires significantly smaller doses than traditional vaccines. This drastically reduces production costs, making it a more viable option for widespread use in livestock and companion animals, particularly in resource-constrained regions.
  2. No Cold Chain Required: Unlike most mRNA vaccines, our DNA-based vaccines are stable at ambient temperatures. This eliminates the need for expensive cold storage and transportation systems, which are significant barriers to vaccine distribution, especially in rural areas.
  3. Longer Duration of Efficacy: Our platform enables vaccines and therapeutics to have a much longer duration of action, which means fewer doses are needed. This not only reduces costs for producers but also increases the practicality of disease prevention on a large scale.
  4. Versatility Across Species and Pathogens: Our Gemini platform is adaptable to a wide range of pathogens and can be tailored to different animal species, making it a flexible tool for addressing multiple health challenges within the animal kingdom.

Eyam’s Role in the Future of Animal Health

The global animal health industry is growing, driven by economic pressures and the need for better disease control. Eyam is positioned at the forefront of this movement, offering transformative solutions that are not only cost-effective but also scalable and long-lasting. Our entrance into the animal health sector isn’t just a business opportunity—it’s a commitment to improving animal welfare, advancing global public health, and securing the future of our food systems.

Thank you for your continued trust and support as we forge new paths in innovation. Together, we are shaping the future of both human and animal health.

Share this post

The Latest

The post Innovating Animal Health with Eyam’s Cost-Effective, Long-Lasting Vaccines appeared first on Eyam Health.

]]> MPox on the Rise: Eyam’s Innovative Response to a Global Health Crisis https://eyamhealth.com/mpox-on-the-rise-eyams-innovative-response-to-a-global-health-crisis/?utm_source=rss&utm_medium=rss&utm_campaign=mpox-on-the-rise-eyams-innovative-response-to-a-global-health-crisis Wed, 18 Sep 2024 17:04:54 +0000 https://eyamhealth.com/?p=3733 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post MPox on the Rise: Eyam’s Innovative Response to a Global Health Crisis appeared first on Eyam Health.

]]>

MPox on the Rise: Eyam’s Innovative Response to a Global Health Crisis

September 06, 2024

By Ryan M. Thomas

MPox in the News:

With the recent award to the UBC/Eyam partnership for the development of an MPox vaccine and the W.H.O. Director General declaration of a “Public Health Emergency of International Concern” regarding the outbreak of the MPox (Monkey Pox) virus, I thought it was timely to address the current situation.

The media has covered this event from different angles over the last month, and as we attempt to do each month, we’ll cover the facts with an eye towards integral objectivity.

First, what is a Public Health Emergency of International Concern (PHEIC)?

On August 13, 2024 the CDC of Africa declared MPox a Public Health Emergency of Continental Security, estimating that it would take $4B to control the situation.

A Public Health Emergency of International Concern (PHEIC) is an extraordinary event declared by the World Health Organization (WHO) when a disease outbreak or other public health event poses a risk to multiple countries and requires a coordinated international response. The declaration is made under the International Health Regulations (IHR), a legally binding framework agreed upon by 196 countries to help the international community prevent and respond to acute public health risks that have the potential to cross borders and threaten people worldwide.

What does it mean when the WHO declares a PHEIC?

When the WHO declares a PHEIC, it signals that the situation is serious, unusual, or unexpected, and that it carries implications for public health beyond the affected country’s national borders. The declaration triggers international cooperation (funding) and can lead to recommendations on travel, trade, quarantine measures, and the distribution of medical resources. It also mobilizes additional resources and expertise to contain and mitigate the spread of the disease. The regions most affected by MPox, would also be available to receive funding and additional resources with the intention of controlling and containing the spread of the disease.

What is MPox?

MPox is a viral disease that currently primarily occurs in central and western Africa. It is caused by the monkeypox virus, which belongs to the same family of viruses as smallpox. While similar to smallpox, MPox is generally less severe but can still lead to serious health complications.

How does MPox spread?

MPox can spread to humans through direct contact with the blood, bodily fluids, or skin lesions of infected animals. Human-to-human transmission occurs through respiratory droplets, direct contact with an infected person’s lesions or bodily fluids, or contact with contaminated materials like bedding.

The MPox Vaccine Initiative

In partnership with UBC, and funding from CHIR, Eyam’s Jennerator design platform is quickly designing vaccine candidates for current and predicted MPox variants. Leveraging the Gemini Platform, the program will aspire to create new vaccines that have the potential to be manufactured at a much lower cost, are scalable for the rapid manufacturing of millions of doses, and aim to be more protective and longer lasting while also more stable at higher temperatures to reach those hard to reach regions.

Our innovative approach leverages recombinant technology, which offers significant advantages including:

  • Safety: Since recombinant vaccines do not contain live pathogens, they are generally safer, especially for immunocompromised individuals.
  • Precision: This technology allows for the production of specific antigens, reducing the risk of side effects related to other components of the pathogen.
  • Scalability: Recombinant technology facilitates large-scale production, which is essential during pandemics or widespread vaccination campaigns.
  • Stability: Recombinant vaccines often have better stability and can be stored and transported more easily than some live vaccines – critical to effectively reach the outbreak areas in Central and West Africa.

It’s a BHAG (big hairy audacious goal) and our technology and team are up to the task.

Eyam is committed to using cutting-edge technologies in collaboration with strategic partners to create vaccines that not only address current health challenges but also anticipate future needs. We believe that our work with UBC on the MPox vaccine will play a crucial role in preventing outbreaks and protecting communities worldwide.

We are excited about the progress we’ve made and are grateful for your continued support as we work towards making this vaccine a reality. Together, we are shaping the future of public health and making strides in our mission to develop next-generation vaccines and therapeutics.

 

MPox on the Rise: Eyam’s Innovative Response to a Global Health Crisis

September 06, 2024

By Ryan M. Thomas

MPox in the News:

With the recent award to the UBC/Eyam partnership for the development of an MPox vaccine and the W.H.O. Director General declaration of a “Public Health Emergency of International Concern” regarding the outbreak of the MPox (Monkey Pox) virus, I thought it was timely to address the current situation.

The media has covered this event from different angles over the last month, and as we attempt to do each month, we’ll cover the facts with an eye towards integral objectivity.

First, what is a Public Health Emergency of International Concern (PHEIC)?

On August 13, 2024 the CDC of Africa declared MPox a Public Health Emergency of Continental Security, estimating that it would take $4B to control the situation.

A Public Health Emergency of International Concern (PHEIC) is an extraordinary event declared by the World Health Organization (WHO) when a disease outbreak or other public health event poses a risk to multiple countries and requires a coordinated international response. The declaration is made under the International Health Regulations (IHR), a legally binding framework agreed upon by 196 countries to help the international community prevent and respond to acute public health risks that have the potential to cross borders and threaten people worldwide.

What does it mean when the WHO declares a PHEIC?

When the WHO declares a PHEIC, it signals that the situation is serious, unusual, or unexpected, and that it carries implications for public health beyond the affected country’s national borders. The declaration triggers international cooperation (funding) and can lead to recommendations on travel, trade, quarantine measures, and the distribution of medical resources. It also mobilizes additional resources and expertise to contain and mitigate the spread of the disease. The regions most affected by MPox, would also be available to receive funding and additional resources with the intention of controlling and containing the spread of the disease.

What is MPox?

MPox is a viral disease that currently primarily occurs in central and western Africa. It is caused by the monkeypox virus, which belongs to the same family of viruses as smallpox. While similar to smallpox, MPox is generally less severe but can still lead to serious health complications.

How does MPox spread?

MPox can spread to humans through direct contact with the blood, bodily fluids, or skin lesions of infected animals. Human-to-human transmission occurs through respiratory droplets, direct contact with an infected person’s lesions or bodily fluids, or contact with contaminated materials like bedding.

The MPox Vaccine Initiative

In partnership with UBC, and funding from CHIR, Eyam’s Jennerator design platform is quickly designing vaccine candidates for current and predicted MPox variants. Leveraging the Gemini Platform, the program will aspire to create new vaccines that have the potential to be manufactured at a much lower cost, are scalable for the rapid manufacturing of millions of doses, and aim to be more protective and longer lasting while also more stable at higher temperatures to reach those hard to reach regions.

Our innovative approach leverages recombinant technology, which offers significant advantages including:

  • Safety: Since recombinant vaccines do not contain live pathogens, they are generally safer, especially for immunocompromised individuals.
  • Precision: This technology allows for the production of specific antigens, reducing the risk of side effects related to other components of the pathogen.
  • Scalability: Recombinant technology facilitates large-scale production, which is essential during pandemics or widespread vaccination campaigns.
  • Stability: Recombinant vaccines often have better stability and can be stored and transported more easily than some live vaccines – critical to effectively reach the outbreak areas in Central and West Africa.

It’s a BHAG (big hairy audacious goal) and our technology and team are up to the task.

Eyam is committed to using cutting-edge technologies in collaboration with strategic partners to create vaccines that not only address current health challenges but also anticipate future needs. We believe that our work with UBC on the MPox vaccine will play a crucial role in preventing outbreaks and protecting communities worldwide.

We are excited about the progress we’ve made and are grateful for your continued support as we work towards making this vaccine a reality. Together, we are shaping the future of public health and making strides in our mission to develop next-generation vaccines and therapeutics.

Share this post

The Latest

The post MPox on the Rise: Eyam’s Innovative Response to a Global Health Crisis appeared first on Eyam Health.

]]> Eyam Vaccines and Immunotherapeutics Secures Global Health Grant to Advance Gemini Expression Platform https://eyamhealth.com/eyam-vaccines-and-immunotherapeutics-secures-global-health-grant-to-advance-gemini-expression-platform/?utm_source=rss&utm_medium=rss&utm_campaign=eyam-vaccines-and-immunotherapeutics-secures-global-health-grant-to-advance-gemini-expression-platform Tue, 10 Sep 2024 16:07:40 +0000 https://eyamhealth.com/?p=3726 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Eyam Vaccines and Immunotherapeutics Secures Global Health Grant to Advance Gemini Expression Platform appeared first on Eyam Health.

]]>

Eyam Vaccines and Immunotherapeutics Secures Global Health Grant to Advance Gemini Expression Platform

Published: September 10, 2024

VANCOUVER, BC / ACCESSWIRE / September 10, 2024 / Eyam Vaccines and Immunotherapeutics is pleased to announce a new grant from the Bill & Melinda Gates Foundation to support the further development of its Gemini expression platform. The goal of this project is to further develop the platform's potential to deliver durable expression of a protein therapeutic, marking an important step in demonstrating the broader applications of this innovative technology.

This study will utilize a monoclonal antibody as a tool to explore how effectively the expression platform can generate sustained expression of the therapeutic protein.

"This grant represents a key milestone for our Gemini platform," said Ryan M. Thomas, CEO of Eyam Vaccines. "By demonstrating the potential of this technology to produce durable protein therapeutics, we can unlock new opportunities for developing long-lasting, low-cost treatments across a range of diseases."

Dr. Terry Pearson, member of Eyam's Board of Directors and an expert in monoclonal antibody technologies emphasized, "The ability of the Gemini expression platform to provide sustained protein expression paves the way for improving monoclonal antibody therapies. This technology could substantially enhance treatment effectiveness and patient compliance by reducing the need for frequent dosing."

Advancing the Gemini Platform

Eyam's Gemini Platform represents a breakthrough in the delivery of therapeutic proteins, offering the possibility of sustained therapeutic effects with minimal dosing. This capability could transform how protein-based therapies are delivered, potentially reducing the need for frequent treatments and enhancing patient outcomes.

Dr. Wilfred Jefferies, Chief Scientific Officer at Eyam, remarked, "The Gemini Platform represents a significant advance in therapeutic delivery. Its novel approach to achieving consistent, long-term protein expression could redefine how we develop and administer protein-based therapies."

Next Steps

The proof-of-concept study will begin immediately, focusing on preclinical evaluations to validate the platform's ability to deliver consistent, long-term protein expression. If successful, this project could pave the way for further exploration of the Gemini expression platform across a range of therapeutic areas beyond infectious diseases.

About Eyam Vaccines and Immunotherapeutics

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, please contact:

Samad Raza
Business Analyst
[email protected]
+1 (778) 381-1075

View source version on accesswire.com:

https://www.accesswire.com/914979/eyam-vaccines-and-immunotherapeutics-secures-global-health-grant-to-advance-gemini-expression-platform

Eyam Vaccines and Immunotherapeutics Secures Global Health Grant to Advance Gemini Expression Platform

Published: September 10, 2024

VANCOUVER, BC / ACCESSWIRE / September 10, 2024 / Eyam Vaccines and Immunotherapeutics is pleased to announce a new grant from the Bill & Melinda Gates Foundation to support the further development of its Gemini expression platform. The goal of this project is to further develop the platform's potential to deliver durable expression of a protein therapeutic, marking an important step in demonstrating the broader applications of this innovative technology.

This study will utilize a monoclonal antibody as a tool to explore how effectively the expression platform can generate sustained expression of the therapeutic protein.

"This grant represents a key milestone for our Gemini platform," said Ryan M. Thomas, CEO of Eyam Vaccines. "By demonstrating the potential of this technology to produce durable protein therapeutics, we can unlock new opportunities for developing long-lasting, low-cost treatments across a range of diseases."

Dr. Terry Pearson, member of Eyam's Board of Directors and an expert in monoclonal antibody technologies emphasized, "The ability of the Gemini expression platform to provide sustained protein expression paves the way for improving monoclonal antibody therapies. This technology could substantially enhance treatment effectiveness and patient compliance by reducing the need for frequent dosing."

Advancing the Gemini Platform

Eyam's Gemini Platform represents a breakthrough in the delivery of therapeutic proteins, offering the possibility of sustained therapeutic effects with minimal dosing. This capability could transform how protein-based therapies are delivered, potentially reducing the need for frequent treatments and enhancing patient outcomes.

Dr. Wilfred Jefferies, Chief Scientific Officer at Eyam, remarked, "The Gemini Platform represents a significant advance in therapeutic delivery. Its novel approach to achieving consistent, long-term protein expression could redefine how we develop and administer protein-based therapies."

Next Steps

The proof-of-concept study will begin immediately, focusing on preclinical evaluations to validate the platform's ability to deliver consistent, long-term protein expression. If successful, this project could pave the way for further exploration of the Gemini expression platform across a range of therapeutic areas beyond infectious diseases.

About Eyam Vaccines and Immunotherapeutics

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, please contact:

Samad Raza
Business Analyst
[email protected]
+1 (778) 381-1075

View source version on accesswire.com:

https://www.accesswire.com/914979/eyam-vaccines-and-immunotherapeutics-secures-global-health-grant-to-advance-gemini-expression-platform

Share this post

The Latest

The post Eyam Vaccines and Immunotherapeutics Secures Global Health Grant to Advance Gemini Expression Platform appeared first on Eyam Health.

]]> Navigating Biotech’s Future: AI-Driven Innovations and Market Dynamics https://eyamhealth.com/navigating-biotechs-future-ai-driven-innovations-and-market-dynamics/?utm_source=rss&utm_medium=rss&utm_campaign=navigating-biotechs-future-ai-driven-innovations-and-market-dynamics Wed, 07 Aug 2024 21:58:09 +0000 https://eyamhealth.com/?p=3706 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Navigating Biotech’s Future: AI-Driven Innovations and Market Dynamics appeared first on Eyam Health.

]]>

Navigating Biotech’s Future: AI-Driven Innovations and Market Dynamics

August 07, 2024

By Ryan M. Thomas

August is already off to a chaotic start with increased volatility in the financial markets and uncertainty of war in the Middle East.

It’s a good time to remember that biotech investments are generally not correlated with the movements of real estate or the broader market. Valuation in biotech is driven by innovation, technology validation, product fit and market size, and is also often impacted by interest rates.

The impact of lower interest rates is really something to be highlighted here. As interest rates fall, the cost of capital decreases, investor appetite for risk increases, debt financing becomes more attractive and M&A activity heats up. All of these factors are positive drivers of biotech valuation.

With the Bank of Canada now lowering interest rates twice (50 bps) this summer, and the Federal Reserve likely to catch up next month, the environment is becoming increasingly favorable for biotech companies.

One of Eyam’s Board Members, Wolfgang Koester, has been regularly on Fox Business News speaking about how the Federal Reserve has been holding back too much and needs to catch up. He’s also become a trusted voice on the impact of Artificial Intelligence on many industries from financial services to the value creation of accelerating drug development in biotech.

As we advance into an era of rapid technological innovation, led by AI, it’s crucial to address the emerging trends and challenges in medicine and biotech. Today, I’d like to delve deeply into the importance of using AI-driven and machine learning drug design platforms with customized delivery systems, highlighting both the opportunities and the obstacles that will need to be overcome.

An AI Bubble?

Artificial intelligence is undoubtedly the buzzword of the decade. Across industries, companies are integrating some form of AI into their operations, hoping to harness its potential to revolutionize their fields. However, in the realm of biotech, there’s a growing disparity between the hype and the tangible commercial products. Many firms adopt AI to attract investors and media attention, but few succeed in converting that interest into viable, market-ready solutions.

This phenomenon, often referred to as the “AI bubble,” highlights a critical challenge: the difference between superficial integration of AI and deep, functional application using machine learning tools. At Eyam, we believe that true innovation requires not just the adoption of AI, but its strategic integration into the core processes of vaccine and therapeutic design and development. This involves not only leveraging AI for data analysis and prediction but also ensuring that the AI systems are “vector aware,” meaning they are designed with a deep understanding of the delivery mechanisms required for effective drug performance.

The Vector Awareness of Eyam’s Jennerator Platform

The significance of vector awareness cannot be overstated. In vaccine and therapeutic design, a molecule’s therapeutic potential is only as good as its ability to reach the target site within the body. Traditional drug design often overlooks this critical aspect, focusing solely on the molecular interactions without considering the delivery vehicle. This approach is actually high risk and can lead to increased failures in clinical trials, where a drug that works perfectly in vitro (“In vitro” is a Latin term meaning “in glass.” It refers to studies and experiments conducted outside of living organisms, typically in a controlled laboratory environment, such as in test tubes, Petri dishes, or culture flasks.) fails to perform in vivo (“In vivo” is a Latin term meaning “within the living.” It refers to studies and experiments conducted in living organisms, such as animals or humans) due to delivery issues.

Our Jennerator platform at Eyam stands out because it incorporates vector awareness into its AI-driven design process. This means that from the very beginning, our platform de-risks the process and considers how a drug will be delivered, ensuring that the designed molecules are not only potent but also capable of being effectively transported to and absorbed by the target cells.

  1. Integrated Bioinformatics and Vector Optimization: The Jennerator platform combines advanced bioinformatics with comprehensive vector optimization. This dual approach ensures that every payload designed is tailored for both efficacy and deliverability. By understanding the delivery system that carries the payload within the body, our AI can optimize solutions before synthesis and testing.
  2. Efficiency and Precision: Traditional drug design can be a lengthy process, often involving trial and error to achieve the right formulation. The Jennerator, however, accelerates this process by using AI to predict and optimize molecular interactions and delivery mechanisms. This not only shortens the development timeline but also increases the likelihood of success in clinical trials.
  3. Real-World Impact: The real-world implications of this approach are profound. By ensuring that our vaccines and therapeutics are optimized for delivery, we can reduce dosages, minimize side effects, and enhance efficacy. This not only improves patient outcomes but also lowers production and distribution costs, making advanced therapies more accessible globally.

Challenges and Pitfalls in AI-Driven Drug Design

While the potential of AI in drug design is immense, it’s essential to recognize and address the challenges that come with it. The AI bubble in biotechnology underscores the need for a realistic and grounded approach.

Here are some common pitfalls and how we at Eyam navigate them:

  1. Data Quality and Availability: AI systems are only as good as the data they are trained on. In the field of drug design, obtaining high-quality, comprehensive datasets can be challenging. Incomplete or biased data can lead to inaccurate predictions and ineffective drugs. At Eyam, we prioritize data integrity and utilize extensive datasets that include genetic, proteomic, and clinical information to train our AI systems.
  2. Computational and Technical Constraints: The complexity of biological systems requires sophisticated computational tools and infrastructure. Many companies lack the necessary resources to implement an end-to-end solution that Eyam’s developed.
  3. Integration with Delivery Systems: As mentioned, the design of a drug is only half the battle; ensuring its effective delivery is equally critical. Many AI platforms fail to account for this, leading to promising molecules or payload that cannot be effectively used in clinical settings. Eyam’s Jennerator platform addresses this by incorporating vector awareness, optimizing both the drug design and its delivery mechanism.
  4. Regulatory and Ethical Considerations: The use of AI in healthcare brings up numerous regulatory and ethical questions. Ensuring compliance with international standards and addressing ethical concerns is paramount. Eyam is committed to transparency and adheres to stringent regulatory guidelines to ensure our AI-driven processes are ethical and safe.

Ethical Concerns in AI-Driven Drug Design

As we forge ahead with AI in drug design, it’s important to remember the great responsibility in harnessing this technology. While AI offers unprecedented opportunities for innovation, it also poses ethical challenges that must be addressed to ensure responsible and equitable use.

Over the next several months, we’ll be discussing in more detail the importance of becoming a leader not only for the design and development of new vaccines and therapeutics with our AI driven technologies, but also how we aim to do so ethically.

The Jennerator Platform: A Case Study in Effective AI Integration

To illustrate the transformative potential of our Jennerator platform, let’s consider a recent case study from our research and development efforts. One of the critical challenges in vaccine development is creating formulations that not only induce a strong immune response but also maintain stability and efficacy across diverse populations and environments.

Our Jennerator platform was tasked with developing a new vaccine candidate for a viral pathogen with significant genetic variability. Traditional approaches had struggled to create a formulation that could effectively target all strains of the virus. Using Jennerator, we were able to analyze extensive genetic and proteomic data to identify conserved regions of the virus that could serve as universal targets for the immune system.

The Jennerator’s vector awareness capabilities allowed us to design vaccine payloads that were optimized for both efficacy and delivery. This included ensuring that the vaccine components could be effectively packaged within our proprietary delivery vectors and that they would remain stable and potent under various storage conditions.

The results are promising: the AI-designed vaccine candidates are demonstrating strong data in preclinical trials, with the ability to express payloads in five open reading frames – a technological jump from the one to two open reading frames currently in the market. Additionally, the optimized delivery system ensured that the vaccine could be stored and transported without the need for ultra-cold temperatures, making it more accessible for global distribution.

The Future of AI in Biotechnology

As we look to the future, the integration of AI in biotechnology will continue to evolve and expand. The potential applications are vast, from personalized medicine to predictive analytics for disease outbreaks.

At Eyam, we are committed to leading the way in responsible AI innovation. Our Jennerator platform is just one example of how AI can be effectively integrated into drug design to create safer, more effective treatments. By continuing to invest in cutting-edge research and fostering collaborations with leading institutions, we aim to push the boundaries of what’s possible in biotechnology.

Final Thoughts

The integration of AI in drug design represents a significant leap forward for the field of biotechnology. However, it is not without its challenges and ethical considerations. At Eyam, we are dedicated to harnessing the power of AI responsibly and effectively, ensuring that our innovations lead to tangible benefits for patients worldwide.

Our Jennerator platform exemplifies this commitment, combining advanced AI with robust delivery systems to create vaccines and therapeutics that are not only potent but also practical for real-world application. As we move forward, we will continue to prioritize ethical considerations, transparency, and collaboration to ensure that our work serves the greater good.

Thank you for your continued support and engagement. Let’s continue to push the boundaries of science together, ensuring a healthier future for all.

 

Navigating Biotech’s Future: AI-Driven Innovations and Market Dynamics

August 07, 2024

By Ryan M. Thomas

August is already off to a chaotic start with increased volatility in the financial markets and uncertainty of war in the Middle East.

It’s a good time to remember that biotech investments are generally not correlated with the movements of real estate or the broader market. Valuation in biotech is driven by innovation, technology validation, product fit and market size, and is also often impacted by interest rates.

The impact of lower interest rates is really something to be highlighted here. As interest rates fall, the cost of capital decreases, investor appetite for risk increases, debt financing becomes more attractive and M&A activity heats up. All of these factors are positive drivers of biotech valuation.

With the Bank of Canada now lowering interest rates twice (50 bps) this summer, and the Federal Reserve likely to catch up next month, the environment is becoming increasingly favorable for biotech companies.

One of Eyam’s Board Members, Wolfgang Koester, has been regularly on Fox Business News speaking about how the Federal Reserve has been holding back too much and needs to catch up. He’s also become a trusted voice on the impact of Artificial Intelligence on many industries from financial services to the value creation of accelerating drug development in biotech.

As we advance into an era of rapid technological innovation, led by AI, it’s crucial to address the emerging trends and challenges in medicine and biotech. Today, I’d like to delve deeply into the importance of using AI-driven and machine learning drug design platforms with customized delivery systems, highlighting both the opportunities and the obstacles that will need to be overcome.

An AI Bubble?

Artificial intelligence is undoubtedly the buzzword of the decade. Across industries, companies are integrating some form of AI into their operations, hoping to harness its potential to revolutionize their fields. However, in the realm of biotech, there’s a growing disparity between the hype and the tangible commercial products. Many firms adopt AI to attract investors and media attention, but few succeed in converting that interest into viable, market-ready solutions.

This phenomenon, often referred to as the “AI bubble,” highlights a critical challenge: the difference between superficial integration of AI and deep, functional application using machine learning tools. At Eyam, we believe that true innovation requires not just the adoption of AI, but its strategic integration into the core processes of vaccine and therapeutic design and development. This involves not only leveraging AI for data analysis and prediction but also ensuring that the AI systems are “vector aware,” meaning they are designed with a deep understanding of the delivery mechanisms required for effective drug performance.

The Vector Awareness of Eyam’s Jennerator Platform

The significance of vector awareness cannot be overstated. In vaccine and therapeutic design, a molecule’s therapeutic potential is only as good as its ability to reach the target site within the body. Traditional drug design often overlooks this critical aspect, focusing solely on the molecular interactions without considering the delivery vehicle. This approach is actually high risk and can lead to increased failures in clinical trials, where a drug that works perfectly in vitro (“In vitro” is a Latin term meaning “in glass.” It refers to studies and experiments conducted outside of living organisms, typically in a controlled laboratory environment, such as in test tubes, Petri dishes, or culture flasks.) fails to perform in vivo (“In vivo” is a Latin term meaning “within the living.” It refers to studies and experiments conducted in living organisms, such as animals or humans) due to delivery issues.

Our Jennerator platform at Eyam stands out because it incorporates vector awareness into its AI-driven design process. This means that from the very beginning, our platform de-risks the process and considers how a drug will be delivered, ensuring that the designed molecules are not only potent but also capable of being effectively transported to and absorbed by the target cells.

  1. Integrated Bioinformatics and Vector Optimization: The Jennerator platform combines advanced bioinformatics with comprehensive vector optimization. This dual approach ensures that every payload designed is tailored for both efficacy and deliverability. By understanding the delivery system that carries the payload within the body, our AI can optimize solutions before synthesis and testing.
  2. Efficiency and Precision: Traditional drug design can be a lengthy process, often involving trial and error to achieve the right formulation. The Jennerator, however, accelerates this process by using AI to predict and optimize molecular interactions and delivery mechanisms. This not only shortens the development timeline but also increases the likelihood of success in clinical trials.
  3. Real-World Impact: The real-world implications of this approach are profound. By ensuring that our vaccines and therapeutics are optimized for delivery, we can reduce dosages, minimize side effects, and enhance efficacy. This not only improves patient outcomes but also lowers production and distribution costs, making advanced therapies more accessible globally.

Challenges and Pitfalls in AI-Driven Drug Design

While the potential of AI in drug design is immense, it’s essential to recognize and address the challenges that come with it. The AI bubble in biotechnology underscores the need for a realistic and grounded approach.

Here are some common pitfalls and how we at Eyam navigate them:

  1. Data Quality and Availability: AI systems are only as good as the data they are trained on. In the field of drug design, obtaining high-quality, comprehensive datasets can be challenging. Incomplete or biased data can lead to inaccurate predictions and ineffective drugs. At Eyam, we prioritize data integrity and utilize extensive datasets that include genetic, proteomic, and clinical information to train our AI systems.
  2. Computational and Technical Constraints: The complexity of biological systems requires sophisticated computational tools and infrastructure. Many companies lack the necessary resources to implement an end-to-end solution that Eyam’s developed.
  3. Integration with Delivery Systems: As mentioned, the design of a drug is only half the battle; ensuring its effective delivery is equally critical. Many AI platforms fail to account for this, leading to promising molecules or payload that cannot be effectively used in clinical settings. Eyam’s Jennerator platform addresses this by incorporating vector awareness, optimizing both the drug design and its delivery mechanism.
  4. Regulatory and Ethical Considerations: The use of AI in healthcare brings up numerous regulatory and ethical questions. Ensuring compliance with international standards and addressing ethical concerns is paramount. Eyam is committed to transparency and adheres to stringent regulatory guidelines to ensure our AI-driven processes are ethical and safe.

Ethical Concerns in AI-Driven Drug Design

As we forge ahead with AI in drug design, it’s important to remember the great responsibility in harnessing this technology. While AI offers unprecedented opportunities for innovation, it also poses ethical challenges that must be addressed to ensure responsible and equitable use.

Over the next several months, we’ll be discussing in more detail the importance of becoming a leader not only for the design and development of new vaccines and therapeutics with our AI driven technologies, but also how we aim to do so ethically.

The Jennerator Platform: A Case Study in Effective AI Integration

To illustrate the transformative potential of our Jennerator platform, let’s consider a recent case study from our research and development efforts. One of the critical challenges in vaccine development is creating formulations that not only induce a strong immune response but also maintain stability and efficacy across diverse populations and environments.

Our Jennerator platform was tasked with developing a new vaccine candidate for a viral pathogen with significant genetic variability. Traditional approaches had struggled to create a formulation that could effectively target all strains of the virus. Using Jennerator, we were able to analyze extensive genetic and proteomic data to identify conserved regions of the virus that could serve as universal targets for the immune system.

The Jennerator’s vector awareness capabilities allowed us to design vaccine payloads that were optimized for both efficacy and delivery. This included ensuring that the vaccine components could be effectively packaged within our proprietary delivery vectors and that they would remain stable and potent under various storage conditions.

The results are promising: the AI-designed vaccine candidates are demonstrating strong data in preclinical trials, with the ability to express payloads in five open reading frames – a technological jump from the one to two open reading frames currently in the market. Additionally, the optimized delivery system ensured that the vaccine could be stored and transported without the need for ultra-cold temperatures, making it more accessible for global distribution.

The Future of AI in Biotechnology

As we look to the future, the integration of AI in biotechnology will continue to evolve and expand. The potential applications are vast, from personalized medicine to predictive analytics for disease outbreaks.

At Eyam, we are committed to leading the way in responsible AI innovation. Our Jennerator platform is just one example of how AI can be effectively integrated into drug design to create safer, more effective treatments. By continuing to invest in cutting-edge research and fostering collaborations with leading institutions, we aim to push the boundaries of what’s possible in biotechnology.

Final Thoughts

The integration of AI in drug design represents a significant leap forward for the field of biotechnology. However, it is not without its challenges and ethical considerations. At Eyam, we are dedicated to harnessing the power of AI responsibly and effectively, ensuring that our innovations lead to tangible benefits for patients worldwide.

Our Jennerator platform exemplifies this commitment, combining advanced AI with robust delivery systems to create vaccines and therapeutics that are not only potent but also practical for real-world application. As we move forward, we will continue to prioritize ethical considerations, transparency, and collaboration to ensure that our work serves the greater good.

Thank you for your continued support and engagement. Let’s continue to push the boundaries of science together, ensuring a healthier future for all.

Share this post

The Latest

The post Navigating Biotech’s Future: AI-Driven Innovations and Market Dynamics appeared first on Eyam Health.

]]> Eyam Announces Nicholas Franco Appointment to Board of Advisors https://eyamhealth.com/eyam-announces-nicholas-franco-appointment-to-board-of-advisors/?utm_source=rss&utm_medium=rss&utm_campaign=eyam-announces-nicholas-franco-appointment-to-board-of-advisors Mon, 24 Jun 2024 16:39:55 +0000 https://eyamhealth.com/?p=3695 Over the last several months, it seems like we’ve been on a COVID-19 Rollercoaster. First, the long-awaited vaccines rolled out and a subsequent decline in cases was reported in regions where vaccines were rolled out quickly.

The post Eyam Announces Nicholas Franco Appointment to Board of Advisors appeared first on Eyam Health.

]]>

Eyam Announces Nicholas Franco Appointment to Board of Advisors

Published: June 24, 2024

VANCOUVER, BC / ACCESSWIRE / June 24, 2024 / Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco brings a wealth of experience and strategic vision from his extensive career in the pharmaceutical industry.

Mr. Franco has held key executive level leadership positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical Companies of Johnson & Johnson. His expertise in business development, commercialization and leading organizations has significantly contributed to the growth and innovation in the companies he has served.

With over three decades of experience, Mr. Franco has been pivotal in driving business development and strategic growth in leading pharmaceutical companies, including experience in research, marketing, sales and business development across several therapeutic areas and geographies.

Prior to Janssen, he was the Executive Vice President and Chief Business Officer at Actelion which was later acquired by Janssen in 2017 for $30B. At Novartis, Mr. Franco held several leadership roles including Global Head of Negotiations, Primary Care BD&L, Global Head of Novartis Ophthalmics and Global Head, Neuroscience Business Franchise.

"Eyam is excited to welcome Nicholas as a member of our Advisory Board. His skills, experience and contacts in business development will immediately translate into new opportunities for Eyam's technologies."

"I'm excited to join Ryan and the Eyam team in maximizing the value of their innovative self-amplifying oligonucleotide products and technologies to provide physicians better options for difficult-to-treat diseases," says Nicholas Franco.

Mr. Franco's appointment aligns with Eyam's commitment to strengthening its leadership team and maximizing its business development efforts to drive forward its innovative biotech solutions.

About Eyam:

Eyam aims to revolutionize healthcare through the development and commercialization of advanced vaccine and therapeutic platforms. Eyam's focus includes technologies across four key areas: infectious disease, oncology, chronic disease and animal health.

Eyam, is named in honor of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next generation technologies to prevent and treat disease on a global scale.

contact info:

Samad Raza,
Business and Data Analyst
[email protected]
+1 (778) 381-1075

View source version on accesswire.com:

https://www.accesswire.com/880835/eyam-announces-nicholas-franco-appointment-to-board-of-advisors

Eyam Announces Nicholas Franco Appointment to Board of Advisors

Published: June 24, 2024

VANCOUVER, BC / ACCESSWIRE / June 24, 2024 / Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco brings a wealth of experience and strategic vision from his extensive career in the pharmaceutical industry.

Mr. Franco has held key executive level leadership positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical Companies of Johnson & Johnson. His expertise in business development, commercialization and leading organizations has significantly contributed to the growth and innovation in the companies he has served.

With over three decades of experience, Mr. Franco has been pivotal in driving business development and strategic growth in leading pharmaceutical companies, including experience in research, marketing, sales and business development across several therapeutic areas and geographies.

Prior to Janssen, he was the Executive Vice President and Chief Business Officer at Actelion which was later acquired by Janssen in 2017 for $30B. At Novartis, Mr. Franco held several leadership roles including Global Head of Negotiations, Primary Care BD&L, Global Head of Novartis Ophthalmics and Global Head, Neuroscience Business Franchise.

"Eyam is excited to welcome Nicholas as a member of our Advisory Board. His skills, experience and contacts in business development will immediately translate into new opportunities for Eyam's technologies."

"I'm excited to join Ryan and the Eyam team in maximizing the value of their innovative self-amplifying oligonucleotide products and technologies to provide physicians better options for difficult-to-treat diseases," says Nicholas Franco.

Mr. Franco's appointment aligns with Eyam's commitment to strengthening its leadership team and maximizing its business development efforts to drive forward its innovative biotech solutions.

About Eyam:

Eyam aims to revolutionize healthcare through the development and commercialization of advanced vaccine and therapeutic platforms. Eyam's focus includes technologies across four key areas: infectious disease, oncology, chronic disease and animal health.

Eyam, is named in honor of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next generation technologies to prevent and treat disease on a global scale.

contact info:

Samad Raza,
Business and Data Analyst
[email protected]
+1 (778) 381-1075

View source version on accesswire.com:

https://www.accesswire.com/880835/eyam-announces-nicholas-franco-appointment-to-board-of-advisors

Share this post

The Latest

The post Eyam Announces Nicholas Franco Appointment to Board of Advisors appeared first on Eyam Health.

]]>